AstraZeneca ‘probably couldn’t run Gilead any better:’ analy...

AstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to be that there would anyway be little value in such a

New remdesivir study leaves clinicians guessing about its ef...

The latest tranche of data with Gilead Sciences’ remdesivir in COVID-19 patients isn’t making it easy to gauge how well it is working.

Gilead trumpets data with newly-bought magrolimab in blood c...

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.

Gilead slides as second Chinese trial of remdesivir is stopp...

First study of Gilead’s remdesivir in COVID-19 reveals littl...

EMA clears compassionate use of Gilead’s remdesivir for COVI...